On November 4, 2026 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, reported financial and corporate updates for the quarter ended September 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Martin Zügel, Interim CEO of AC Immune SA, commented: "This quarter was an important period for AC Immune as we saw our pipeline of wholly-owned programs delivering positive clinical results. Our proprietary programs targeting a-syn have seen important developments including encouraging clinical results for ACI-7104 in Parkinson’s disease and the recent nomination of a lead small-molecule Morphomer candidate drug which will now be entering preclinical development. Together with the initial hsCRP results in the Phase 1b trial to be reported in the early part of next year, we believe we are well positioned across our portfolio moving into 2027."
Q3 2026 and Subsequent Highlights: Wholly-Owned Programs
ACI-7104: anti-a-syn active immunotherapy
● Positive safety and immunogenicity results reported through week-100 in Part 1 of VacSYn, the ongoing Phase 2 trial evaluating ACI-7104 in patients with early-stage Parkinson’s disease.
● Strong immunogenicity demonstrated, with 100% response rate after three immunizations, clear antibody penetration into the cerebrospinal fluid (CSF) and preliminary signals for target engagement.
● Exploratory correlation analyses identified trends for a potential association between immunogenicity (antibody levels) and disease activity measures.
● Data will be available before year-end on the characterization of ACI-7104-induced antibodies including their a-syn binding properties
● Discussions with FDA regarding future development path planned for early 2027.
● ACI-7104 also received FDA Fast Track designation and clearance of its Investigational New Drug (IND) application during the period.
Morphomer-a-syn small molecule program
● Lead candidate Morphomer small-molecule drug targeting a-syn has been selected.
● In vitro results have confirmed its potent inhibition of a-syn aggregation. Early-stage results will be presented in due course at an upcoming scientific conference.
● Preclinical development has now been initiated to take the candidate forward.
ACI-19764: small molecule, brain-penetrant NLRP3 inhibitor program
● Results in healthy volunteers were reported from the Phase 1 clinical trial showing the compound was safe and well-tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration.
● Based on pharmacokinetic data, the therapeutic dose is expected to be ≤10mg once daily.
● The development program continues in a Phase 1b trial evaluating ACI-19764’s anti-inflammatory activity in patients with cardiovascular disease risk (elevated hsCRP), with initial results expected early in 2027.
Corporate Governance
● Mr. Tom Graney was elected to the Board of Directors at the Extraordinary General Meeting (EGM) held on October 2nd and will join the Audit and Finance Committee. After several years of service, Dr. Carl June stepped down from the Board of Directors and we thank him sincerely for his contribution and wish him well for the future.
Anticipated near-term news
Program
News
Expected in
ACI-7104
anti-a-syn active immunotherapy
characterization of ACI-7104-induced antibodies including a-syn binding properties
H2 2026
ACI-19764
NLRP3 inhibitor
Results from Phase 1b trial in patient cohort with elevated hsCRP
H1 2027
Analysis of Financial Statements for the Quarter Ended September 30, 2026
● Cash Position: The Company had total cash resources of CHF 73.9 million (CHF 91.4 million as of December 31, 2025), composed of CHF 18.7 million in cash and cash equivalents and CHF 55.2 million in short-term financial assets. The Company’s cash resources are expected to provide sufficient capital to last into Q1 2028, excluding potential milestone payments.
● Revenue: Total revenues for the three months ended September 30, 2026 and 2025 were CHF 3.2 million and CHF 0.9 million, respectively. The increase was due to the recognition of revenues under the Takeda arrangements, which include recognition of the additional consideration received for the AD4 Cohort in 2026.
● R&D expenditures: R&D expenses for the three months ended September 30, 2026, were CHF 9.9 million, compared with CHF 13.1 million for the comparable period in 2025. The decrease was partly due to lower personnel and operational spend of CHF 2.2 million and a decrease of CHF 1.9 million in our discovery and preclinical programs following the restructuring in the prior year. These changes were offset by a net increase of CHF 1.0 million in our clinical programs.
● G&A expenditures: G&A expenses were CHF 3.5 million in the three-month period ended September 30, 2026, compared to CHF 3.6 million for same period in 2025, reflecting a small decrease in personnel related expenses offset by other operational costs.
● Financial result: The financial result was a gain of CHF 1.1 million for the three-month period ended September 30, 2026, compared with a gain of CHF 0.3 million for the comparable period in 2025. The change was primarily driven by more favorable exchange differences in the current quarter.
● IFRS loss for the period: The Company had a net loss of CHF 8.8 million for the three-month period ended September 30, 2026, compared to CHF 15.9 million for the same period in 2025.
(Press release, AC Immune, NOV 4, 2026, View Source [SID1234674154])